Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘Fedratinib’

Over the last decade we have seen great strides taking place in the field of multiple myeloma as the disease has moved from an acute to a more chronic one with the advent of proteasome inhibitors and IMiDs. We’re still not curing many people, however.

The good news is there is now a raft of completely different agents with varying novel targets and modalities emerging at a rapid pace in early to near-term clinical development.

This raises some important strategic questions to think about for the future way beyond which ones look most promising because the bigger question is how will new regimens evolve to challenge the standard of care in each line of treatment?

CAR-T cell therapies are certainly in the mix here, but where will they be optimally used in the future, how do we go about figuring out which people should receive which particular option?

The issues at stake are much more complex than simply asking which BCMA directed therapy is going to be the ‘winner’ because myeloma doesn’t work like this given the preponderence of doublet and triplet regimens.

A better way of exploring new opportunities will be to consider who has what synergies with whom and how might they fit together in a more cogent and coherent fashion.

In order to explore the evolving multiple myeloma landscape, we decided to take a step back and explore the new options from a more strategic perspective. To accomplish this, we interviewed two companies who are active in this niche as well as some specialist thought leaders. It’s a highly relevant time to consider the issues given the broad discussions likely to emerge at JPM21 this week.

We kick off the latest mini-series with a look at the BMS pipeline opportunities in myeloma, who will be followed by J&J tomorrow, and finally discussion with a global expert on Wednesday – so without much ado, let’s roll!

To learn more from our oncology analysis and get a heads up on the latest insights and analysis pertaining to the multiple myeloma landscape, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

This year, the 2013 annual meeting of the American Society of Hematology (ASH) in New Orleans is potentially the meeting of the year with much new data emerging, not only on a multitude of products, but also many biotechs – big and small – not just Pharma.

Last week a chance event unexpectedly found me on the road for two days instead of feverishly browsing the ASH abstracts in real time for the first time in years. I’ve been attending the meeting since the mid 1990’s in various guises, so was quite sad not to be ‘present’ for moment they went live.

Nonetheless, I must pay tribute to the Twitter Bio community who merrily shared and discussed their favourite abstracts on various topics, which made finding and sorting relevant ones much easier and quicker than it might have been. In particular, Patrick Crutcher (@chasingthealpha) of Chimera Research Group did a sterling job of highlighting many key sessions on Twitter, despite being on the west coast for a 9am open time. If you’re not following him on Twitter, check him out!

While reading through all the links and notes I collated, it made sense to write a series of preview posts on different topics. This year, I will be writing five preview posts, with a different topic highlighted in each one:

  • Myelofibrosis
  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia (CLL)
  • Acute Leukemias
  • Lymphomas

For today’s review of Myelofibrosis, the following companies and compounds will be covered:

Companies: Incyte, Novartis, Gilead, Sanofi, BMS, Geron, CTIC, Lilly, Celgene
Compounds: ruxolitinib, INCB039110, momelotinib, fedratinib, BMS-91143, imetelstat, pacritinib, LY2784544, pomalidomide, sonidegib

Note that not all of these agents are JAK inhibitors – others have a different target and can potentially be used in combination with a JAK inhibitor, some are pan JAK inhibitors, some selective and others dual inhibitors. This previews are really mini reviews of the abstracts, meaning it may be easier to print them out and read or contemplate over a cup of coffee.

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

5 Comments
error: Content is protected !!